Immunomedics Aims to Develop Antibody-Based Delivery Tech for RNAi

While the company does not anticipate using the approach to develop RNAi-based drugs itself, it hopes that it will be able to out-license the technology to a partner interested in taking it forward into the clinic.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.